---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-056958"
form_type: "8-K"
ticker: "CLSDQ"
cik: "0001539029"
company_name: "Clearside Biomedical, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T05:49:32.742288+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Clearside reports Q1 net loss $11.8M, $0.17/sh; cash $35.4M; ODYSSEY topline due Q3 2024

## Summary
- Net loss $11.8M ($0.17/sh) vs $9.3M ($0.15) Q1 2023; revenue $230K up from $4K.
- Cash $35.4M expected to fund operations into Q3 2025.
- Phase 2b ODYSSEY trial of CLS-AX in wet AMD topline data expected Q3 2024.
- Appointed Victor Chong as CMO (March 2024) and Tony Gibney to Board (April 2024).
- Completed $15M registered direct offering in Feb 2024; new CPT code for XIPERE effective Jan 1, 2024.

## SEC filing metadata
- accession: 0000950170-24-056958
- form_type: 8-K
- ticker: CLSDQ
- cik: 0001539029
- company_name: Clearside Biomedical, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1539029/000095017024056958/0000950170-24-056958-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1539029/000095017024056958/clsd-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-056958
- JSON: https://secwatch.observer/filing/0000950170-24-056958.json
- Plain text: https://secwatch.observer/filing/0000950170-24-056958.txt

## Key facts
- Earnings Releases
  Clearside Biomedical, Inc. reported first quarter ended March 31, 2024 results: revenue $230,000, net income $11.8 million, EPS $0.17 per share of common stock.
  - Period: first quarter ended March 31, 2024
  - Revenue: $230,000
  - Net income: $11.8 million
  - EPS: $0.17 per share of common stock
  - Result: reported results
  source text: by delivering drug directly to the back of the eye via the SCS Microinjector. First Quarter 2024 Financial Results • License and other revenue for the first quarter of 2024 was $230,000, compared to $4,000 for the first quarter of 2023. • Research and development expenses for the first quarter of 2024 were $5.6 million, compared to $4.5 million for the first
  evidence_url: https://www.sec.gov/Archives/edgar/data/1539029/000095017024056958/0000950170-24-056958-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.